FLT3

下级目录

NameC
SGI-1776 free base
SIM010603
SU-5614
KRC-108
AKN-028
BPR1J-097
BPR1J-340
FLX925 (AMG-925)
UNC-2025
G-749
CGP52421
AFG210
AAE871
AFG206
Ast-487
XL999
N-(1,3-Benzodioxol-5-ylmethyl)-4-benzofuro[3,2-d]pyrimidin-4-yl-1-piperazinecarbothioamide
AUZ454
FI-700
LBW242
TTT-3002
AZD-2932
4SC-203
LY2457546
TG02 (SB1317)
PACRITINIB
SB1578
2-(3,4-Dimethoxy-benzoylamino)-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid amide
3-PHENYL-1H-BENZOFURO[3,2-C]PYRAZOLE
LESTAURTINIB
Tandutinib
AZD1152-HQPA
Linifanib

目录项下的产品

1000669-72-6
1025065-69-3
1032265-67-0
1055412-47-9
1146944-35-5
1175017-90-9
1327167-19-0
1395051-72-5
1401033-86-0
1429881-91-3
1457983-28-6
179237-49-1
228400-22-4
289479-07-8
630122-37-1
630124-46-8
630124-46-8 / MFCD30124468
AST487, also known as NVP-AST487, is a RET kinase inhibitor/FLT3 inhibitor. The RET kinase has emerged as a promising target for the therapy of medullary thyroid cancers (MTC) and of a subset of papillary thyroid cancers. NVP- AST487 has an IC(50) of 0.88 mumol/L on RET kinase, inhibits RET autophosphorylation and activation of downstream effectors, and potently inhibited the growth of human thyroid cancer cell lines with activating mutations of RET but not of lines without RET mutations. NVP- AST487 induced a dose-dependent growth inhibition of xenografts of NIH3T3 cells expressing oncogenic RET, and of the MTC cell line TT in nude mice. NVP- AST487 inhibited calcitonin gene expression in vitro in TT cells, in part, through decreased gene transcription.
1-(4-((4-乙基哌嗪-1-基)甲基)-3-(三氟甲基)苯基)-3-(4-((6-(甲基氨基)嘧啶-4-基)氧基)苯基)脲
705946-27-6
850879-09-3
853299-07-7
866883-79-6
867324-12-7
871037-95-5
883986-34-3
895533-09-2
908265-94-1
908265-94-1 / MFCD008265941
LY2457546 is a potent and orally bioavailable inhibitor of multiple receptor tyrosine kinases involved in angiogenic and tumorigenic signalling. LY2457546 demonstrates potent activity against targets that include VEGFR2 (KDR), PDGFRβ, FLT-3, Tie-2 and members of the Eph family of receptors. In vivo, LY2457546 inhibited VEGF-driven autophosphorylation of lung KDR in the mouse and rat in a dose and concentration dependent manner. LY2457546 was well tolerated and exhibited efficacy in a 13762 syngeneic rat mammary tumor models. Additionally, LY2457546 caused complete regression of well-established tumors in an acute myelogenous leukemia (AML) FLT3-ITD mutant xenograft tumor model. The unique spectrum of target activity, potent in vivo anti-tumor efficacy in a variety of rodent and human solid tumor models, exquisite potency against a clinically relevant model of AML, and non-clinical safety profile justify the advancement of LY2457546 into clinical testing. (source: Invest New Drugs. 2012
937270-47-8
937272-79-2
937273-04-6
301305-73-7
34823-86-4
111358-88-4
387867-13-2
722544-51-6
796967-16-3